

## **Natural postmenopause is associated with an increase in combined cardiovascular risk factors**

**Magdalena Lejsková<sup>1,3,\*</sup>, Štefan Alušík<sup>1,3</sup>, Zdeněk Valenta<sup>2</sup>, Silvia Adámková<sup>3</sup> and Jan Piňha<sup>4</sup>**

<sup>1</sup> Institute for Postgraduate Medical Education, Ruská 2412/85, 100 00 Prague 10, Czech Republic

<sup>2</sup> Department of Medical Informatics, Institute of Computer Science, Academy of Sciences of the Czech Republic, Pod Vodárenskou věží 2, 182 07 Prague, Czech Republic

<sup>3</sup> Department of Medicine I, Thomayer Hospital and Outpatient Clinic, Vídeňská 800, 140 59 Prague 4, Czech Republic

<sup>4</sup> Laboratory of Atherosclerosis Research, Institute of Clinical and Experimental Medicine (IKEM), Vídeňská 1958/9, 140 21 Prague 4, Czech Republic

### **\*CORRESPONDING AUTHOR:**

Magdalena Lejsková, MD, PhD,

1<sup>st</sup> Department of Medicine, Thomayer Hospital and Outpatient Clinic,

Vídeňská 800,

140 21 Prague 4, Czech Republic;

Telephone: + 420 261 083 759; Fax: + 420 241 721 770;

E-mail: [magdalena.lejskova@ftn.cz](mailto:magdalena.lejskova@ftn.cz)

**SHORT TITLE:** Cardiovascular Risk in Menopause

## **SUMMARY**

Cardiovascular disease, while rare in women of reproductive age, is the main cause of mortality in menopause. The purpose of our study was to determine the association of natural menopause with cardiovascular risk factors, including their clustering into metabolic syndrome (MS). A random 5% representative population sample of women aged 45-54 years was examined. In 575 women, we were able to determine their natural reproductive aging status. Multiple regression analysis was used to calculate the association between age, menopausal status, and risk factors under study. After adjustment for age, there was an increase in the odds ratio of developing MS, as defined by NCEP (OR=2.0; 95% CI [1.1; 3.7]), and an increase in plasma lipid ratios (total cholesterol/HDL-C, LDL-C/HDL-C, apolipoprotein-B/apolipoprotein-A1;  $p < 0.05$  for all) in postmenopausal women. Age, but not menopausal status, was associated with some single components of MS; only waist circumference significantly increased after menopause, independently of age. Clustering of risk factors in MS and lipid ratios (combined factors) was strongly associated with menopause whereas worsening of single components of MS was strongly associated with age. In conclusion, based on our results, the menopause may pose a risk to women through clustering of cardiovascular risk factors beyond simple aging.

**KEY WORDS:** menopause, metabolic syndrome, dyslipidemia, cardiovascular disease, central obesity

## **INTRODUCTION**

Compared with age-matched men, women of reproductive age have a low rate of cardiovascular events and low levels of most cardiovascular risk factors. Despite this, the total rate of death from cardiovascular disease as well as from an unhealthy lifestyle, along with

the long life expectancy in developed countries, is higher in women than in men (Roger *et al.* 2011). It is a well-known fact that both artificially induced and natural menopause associated with reduced ovarian function result in an increase in cholesterol levels. There has been emerging evidence showing an increase in obesity and in the prevalence of the metabolic syndrome (MS) (Teede *et al.* 2010), which may affect only the part of the population at higher risk (Lejsková *et al.* 2011) and metabolic effects of menopause may not be unique (Carr 2003, Feng *et al.* 2008), with single MS components not necessarily being identical in the period of their postmenopausal rise (Cho *et al.* 2008). Another problem is separating the effect of menopause from that of aging (Mesch *et al.* 2006). The results of studies assessing menopausal changes of the single components of MS are inconsistent: studies of peri- and postmenopausal women of different ethnics may have a different prevalence of MS and a different ratio between its main components (Feng *et al.* 2008, Inhavivadhana *et al.* 2011).

Prevention of cardiovascular disease is important in middle-aged individuals, even in those at low 10-year cardiovascular risk, yet high lifelong risk (Berry *et al.* 2009). Screening of women entering menopausal transition with slightly increased risk of cardiovascular disease might be helpful in providing early and effective intervention while reducing the lifelong cardiovascular risk in this particular population.

In our previous study (Lejsková *et al.* 2011) we found that the acceleration of MS incidence at the onset of menopause may be accompanied by an increase in insulin resistance only in the part of population at highest risk. The aim of our recent epidemiological study was to assess the effect of menopause on the metabolic risk factors of atherosclerosis, particularly to evaluate clustering of risk factors for cardiovascular disease (RFCVD) in MS and changes in lipid ratios in relation to age and menopausal status.

## **METHODS**

### **Participants**

The study was conducted using a random 5% representative population sample of women aged 45 to 54 years (10-year age range). The median age range was consistent with the mean age of women in perimenopause (McKinlay *et al.* 2008). The age range was selected to include large enough and approximately identical proportions of those still in premenopause and those already postmenopausal, in addition to women in perimenopause lasting less than 4 years. The limitation of the age range to 10 years also made it possible to limit the difference in the age means between fertile and postmenopausal women to an extent necessary to achieve the study goals, that is, to compare some characteristics of women close to menopausal transition with those close after menopause.

The women were selected from the General Health Company registry which keeps a database of all insured individuals. In the Czech Republic, all citizens are required by law to be insured; therefore, the database of insured individuals is a continuously updated population registry. Randomly selected individuals were contacted by mail, and invited to visit a specialist clinic within the same district. A total of 909 women (response rate, 64%) attended the examination. The study protocol was approved by the Institutional Ethics Committee and informed consent was obtained from all participants.

### **Data sources**

A physician-completed questionnaire including each participant's medical history, treatment of hypertension, hyperlipidemia, and diabetes was obtained including the date of therapy initiation. To rule out any potential bias, the physician carefully entered details regarding all prescribed treatments, a thorough gynecological history, and the interval since the last menstrual bleeding.

Body weight, height, and waist circumference were measured with an accuracy of 0.1 kg and 0.5 cm, respectively, according to the World Health Organization MONICA study protocol (Meisinger *et al.* 2002). The waist-to-hip ratio and body mass index (BMI; kg/m<sup>2</sup>) were calculated. Systolic and diastolic blood pressures (SBP, DBP) were measured in the sitting position on the right arm after at least 20 minutes' rest in an outpatient clinic. The mean of the second and third measurements of three consecutive readings was used for analyses.

Blood samples were taken after an overnight fast. Serum total cholesterol and triglyceride (TG) levels were measured using a fully automated (HITACHI 911 autoanalyzer, Tokyo, Japan) enzymatic method (reagents from Boehringer Mannheim, Germany, and Hoffmann-La Roche, Basel, Switzerland). High-density lipoprotein cholesterol (HDL-C) was determined by the same method after precipitation of serum lipoproteins with sodium phosphotungstate and magnesium chloride kits. Serum low-density lipoprotein cholesterol (LDL-C) was measured by an automated method with direct determination using an LDL-C kit from Hoffmann-LaRoche (Basel, Switzerland). All methods of lipoprotein analysis in the laboratory are under permanent control by the Center for Disease Control (CDC), Atlanta, GA, USA. Follicle-stimulating hormone (FSH) was measured using IRMA kits (Immunotech, Prague, Czech Republic). Additional details regarding the methods used in the study are available in the paper by Cífková R *et al.* 2008.

### **Study design**

For the purpose of our study, only women with natural reproductive aging were selected from among all those examined. Excluded were women with surgical menopause (including those with unilateral ovariectomy), women with hormone replacement therapy, and women with ambiguous data. All women had their levels of cardiovascular risk, both “single risk factors”

and “combined risk factors”, determined. The latter included more complicated factors: three lipid ratios and MS as determined using 6 variants of two definitions.

At the end of the study, multiple regression analyses were used to determine the effects of age and menopausal status on each of the cardiovascular risk factors studied.

### **Definitions: menopausal status, combined risk factors**

Of the 909 women examined in the study, there were 575 women with unambiguous data about natural reproductive aging. Preliminary characteristics were used to divide these women into three subgroups using the Stages Reproductive Aging Workshop (STRAW) (Soules *et al.* 2001) criteria by the time since their final/last menstrual period (LMP): a subgroup of women still in premenopause (“Premenopause“ - 351 women: fewer than 33 postmenstrual days), a menopausal transition subgroup (“Perimenopause” - 95 women: 33-365 postmenstrual days), and a postmenopausal one (“Postmenopause”: 129 women: more than 365 postmenstrual days).

Traditional cardiovascular risk factors were established in all groups. Fasting glucose and insulin were used to calculate the insulin resistance index [HOMA-IR, H<sub>O</sub>meostasis Model Assessment of Insulin Resistance = (fasting plasma glucose; mmol/l) × (fasting plasma insulin; mU/l)/22.5] and the insulin sensitivity index [QUICKI, QUantitative Insulin sensitivity ChecK Index = 1/(log(fasting plasma insulin, mU/l) + log(fasting plasma glucose, mmol/l) + log18.01)] (Katz *et al.* 2000).

Lipid ratios were calculated by dividing the plasma levels of proatherogenic and antiatherogenic lipoproteins. The total cholesterol/ HDL-C and the LDL-C/HDL-C ratios are the two longest-used atherogenic lipid ratios shown to be superior to total or LDL-C levels in predicting cardiovascular events (Kinosian *et al.* 1994). In addition, recent studies have suggested that the apolipoprotein B/apolipoprotein A1 ratio is comparable or superior to the above ratios in predicting the development of coronary heart disease (Ingelsson *et al.* 2007).

The study used two definitions of MS: first, the National Cholesterol Education Program Adult Treatment Panel III (NCEP) definition created in 2001 (Grundy *et al.* 2001) and, second, the definition published in 2009 (Alberti *et al.* 2009) and developed by several major organizations in order to unify criteria (Harmonizing the MS). According to both definitions, MS was diagnosed using the original one and variants proposed in the literature. The variants using the NCEP definition were as follows: first, one calculated without pharmacotherapy (NCEP-2001), second, with treatment of diabetes and hypertension (G + BP therapy), and a third one with pharmacotherapy of any of the components (G + BP + LIP therapy). When using the recent definition, Harmonizing the MS, the variants were as follows: first based on the original definition, second with the addition of an increased limit for waist circumference (waist  $\geq$  88cm), and a third one with the addition of an increased limit for glycemia (glycemia  $\geq$  6.1 mmol/l).

### **Statistical methods**

Distributions of all continuous variables were assessed prior to performing statistical analyses. In two cases (variables HOMA-IR and triglycerides), the corresponding distributions were determined as log-normal rather than normal. Therefore, in the two respective cases, the log-transformed rather than original values were entered into the linear regression models which assume a normal error structure. Results of the multiple regressions and multiple logistic regression modeling, including analysis of variance of the modeling terms, are presented in figures with data tables. Age and indicators of menopausal status were entered into all the models as explanatory variables. The effect of menopause on each investigated variable (e.g., total cholesterol, non-HDL cholesterol, etc.) was assessed using tests with the premenopausal period serving as baseline. We studied the effects of age, perimenopause, and postmenopause separately. Results of MS, its parameters, and related factors are presented in Figure 1 while Figure 2 presents results related to the cholesterol lipid spectrum and related ratios.

Summaries of effect sizes for binary variables are presented as odds ratios with 95% confidence intervals.

## **RESULTS**

### **Characteristics**

Among the 575 women with unambiguous natural reproductive aging examined in our study, only 95 women were classified as perimenopausal (33-365 postmenstrual days; Table 1). The majority, 351 women, were no longer than 33 days since their last menstruation (“Premenopause”). The remaining 129 women were more than 365 days since their last menstruation (“Postmenopause”). Women in natural postmenopause had high FSH levels consistent with their postmenopausal status: FSH > 30 IU/l (> 40 IU/l) was seen in 93.3% (90.0%) of women in this subgroup, and the interval since the final menstruation of the eight women with FSH < 30 IU/l was  $3.2 \pm 1.8$  years, consistent with the postmenstrual interval of all women in natural postmenopause ( $4.3 \pm 3.1$  years; median 3.5 years).

Postmenopausal women were older and showed higher levels of atherogenic lipid parameters, BMI, and both markers of abdominal obesity while not differing in age at their last menstrual period. The prevalence of MS using the NCEP definition variants for all study populations together was much lower (14.4% without pharmacotherapy; 16.8% with pharmacotherapy) compared with the Harmonizing MS definition variants (21.6% with waist  $\geq 88$  cm; 27.3% original definition with waist  $\geq 80$  cm).

### **Main results**

When studying the age-adjusted effect of peri- and postmenopause separately (with premenopause representing the baseline), the odds ratio of MS NCEP (Grundy *et al.* 2001) increased significantly only in postmenopause with an OR  $\sim 2$ ,  $p < 0.05$  for all variants (Figure 1). The effect of age was consistently non-significant. By contrast, when using any of the



variants of the more recent definition Harmonizing the MS (Alberti *et al.* 2009) with lower cut points for waist circumference and/or glycemia, the age-adjusted effect of postmenopause did not reach the level of statistical significance. Nevertheless, the age-adjusted OR in the range of 1.269 to 1.598 with quite wide 95% CI suggest a trend similar to MS-NCEP (although weaker), and the association could be possibly significant with a larger sample size.

Among all the 12 single parameters related to MS, the age-adjusted effect of postmenopausal status was evident only on the waist circumference. The age-adjusted increase in waist circumference reached an average of 2.6 cm ( $p=0.091$ ) in perimenopause and 4.0 cm in postmenopause ( $p=0.010$ ). With the other eleven MS-related parameters, the age-adjusted effect of postmenopause did not reach the level of statistical significance. At the same time, the effect of age was significant in only seven parameters (BMI, log-triglycerides, apolipoprotein B, glycemia, systolic blood pressure, and both types of conditions defining hypertension in MS).

A significant effect of age and postmenopause was observed with atherogenic lipid cholesterol fractions (Figure 2). After adjusting for the effect of age and comparing peri- and postmenopause against premenopause separately, the lipid ratios increased significantly only in postmenopause (LDL-C/HDL-C,  $p=0.029$ ; total CHOL/HDL-C,  $p=0.012$ ; Apo-B/Apo-A1,  $p=0.013$ ). Thus, the lipid ratios were shown to reach levels of statistical significance similar to those observed for the incidence of MS using the NCEP definition variants. Furthermore, the effect of age appeared non-significant in all respective models of combined markers that were examined.

Interactions between age and menopausal status were non-significant in any of the monitored variables.

## DISCUSSION

### Clustering of cardiovascular risk factors during menopause

The main goal of this study was to assess the effect of menopause on metabolic cardiovascular risk factors. The results of multiple regression analyses showed it is combined risk markers (lipid atherogenic ratios and MS with higher cut points – NCEP variants) whose increases contribute significantly to the increase in cardiovascular risk seen in postmenopause after adjustment for age. By contrast, single risk factors of MS (except for waist circumference) were associated exclusively with age – and a similar association of MS with age, not with postmenopause, was found when using the more recent definitions with decreased cut points for waist circumference and glycemia (Harmonizing the MS variants). Hence, our results suggest that postmenopause is associated with a clustering of risk factors of MS. Whether this is a causal or associational finding cannot be determined from our data. Women with 1-2 premenopausal risk factors could be more likely at risk of developing additional risk factors and “diagnosticable” MS during menopause than women without premenopausal risk factors. This issue warrants further research, preferably using a prospective study. Logically, NCEP-MS definitions with higher limits associated with higher risk do identify smaller numbers of individuals at higher risk (Cameron 2010, Moebus *et al.* 2007). Our finding that postmenopause, when adjusted for age, is associated with the prevalence of MS-NCEP is another piece of evidence that the most adverse metabolic changes may occur in women entering menopause with a predisposition to MS.

Our results have a biologically plausible explanation: the android body structure with abdominal obesity is associated with an increase in cardiovascular risk levels: increased circulating adhesion molecules in patients with abdominal obesity play an important role in the development of endothelial dysfunction/atherosclerosis (Bosanská *et al.* 2010). There is even experimental evidence that obesity increased the size of myocardial infarction in male,

but not in female Wistar rats (Clark *et al.* 2011). Menopause is known to be associated with a relative increase in android hormonal effects resulting in an increased prevalence of MS (Janssen *et al.* 2008). In a relatively non-risk population, the adverse effects of menopause, even in the presence of an increase in android obesity (larger waist circumference), may not be present (Feng *et al.* 2008). These facts suggest that the level of cardiovascular risk factors may increase, particularly in a (sub)population at higher risk, i.e., in premenopausal women with an a priori any factor(s) of MS or in those with a priori mild dyslipidemia. Provided that the adverse effects are more appreciable in the part of population at risk, a change in the mean values of the index parameter during menopause may not be statistically significant (Lejsková *et al.* 2011).

### **Confounding effect of treated individual risk factors**

While the proportion of women with antihypertensive therapy (“Blood pressure-lowering therapy“ in Table 1) in postmenopause was higher by almost half, this fact virtually did not get reflected in an increase in the prevalence of defined hypertension, which rose by an approx. 6% regardless of the presence/absence of antihypertensive therapy (“SBP  $\geq$  130mmHg or DBP  $\geq$  85mmHg“ rose by 5.4%, with “SBP  $\geq$  130mmHg or DBP  $\geq$  85mmHg or BP-lowering ther.“ increasing by 6.4%). The increase in MS prevalence in postmenopause was unaffected by antihypertensive therapy at all (“NCEP-2001 without therapy“ increased by 13.4% and “NCEP-2001 G+BP therapy“ rose by 13.3%). Similarly, the increase in the prevalence of defined MS in postmenopause was not markedly affected even after inclusion of the criterion fibrate and/or hypoglycemic therapy (“MS NCEP-2001 G+BP+LIP therapy“ rose by 14%). In addition, each of the above definitions was assessed separately to detect even a small potential effect of pharmacotherapy in statistical analysis.

### **Strengths and limitations of the study**

To the best of our knowledge, ours is the first study examining in more detail a potential effect of menopause on cardiovascular risk factor clustering. While the aims of our study were achieved using a random 5% representative population sample without major ethnic differences and within a narrow age range, the cross-sectional design of the study was a limitation to interpretation of its results.

### **CONCLUSION**

The cluster of cardiovascular risk factors referred to as MS, as defined by the NCEP-ATPIII in 2001, and combined lipid markers of cardiovascular risk – lipid atherogenic ratios – was predicted by menopause, not by age. The results of our epidemiological study support the notion that women with lost ovarian function in natural menopause are at risk of developing not only atherogenic dyslipidemia but, also, of clustering of additional cardiovascular risk factors. In this population, it would be particularly women entering menopause with one or two components of MS and/or mild dyslipidemia, on whom efforts to prevent cardiovascular risk factors from clustering should be focused to reduce their lifelong cardiovascular risk.

### **Acknowledgments**

This study was supported by research grant NS10511-3/2009 of the Internal Grant Agency of the Ministry of Health of the Czech Republic and partly supported by the Institutional Research Plan AV0Z10300504 “Computer Science for the Information Society: Models, Algorithms, Applications”.

### **References**

ALBERTI KG, ECKEL RH, GRUNDY SM, ZIMMET PZ, CLEEMAN JI, DONATO KA, FRUCHART JC, JAMES WP, LORIA CM, SMITH SC. Harmonizing the metabolic syndrome: a joint interim statement of

- the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation* **120**: 1640-5, 2009.
- BERRY JD, LIU K, FOLSOM AR, LEWIS CE, CARR JJ, POLAK JF, SHEA S, SIDNEY S, O'LEARY DH, CHAN C, LLOYD-JONES DM. Prevalence and progression of subclinical atherosclerosis in younger adults with low short-term but high lifetime estimated risk for CAD: the coronary artery risk development in young adults and multi-ethnic study of atherosclerosis. *Circulation* **119**: 382-9, 2009.
- BOSANSKÁ L, MICHALSKÝ D, LACINOVÁ Z, DOSTÁLOVÁ I, BÁRTLOVÁ M, HALUZÍKOVÁ D, MATOULEK M, KASALICKÝ M, HALUZÍK M. The influence of obesity and different fat depots on adipose tissue gene expression and protein levels of cell adhesion molecules. *Physiol Res* **59**: 79-88, 2010.
- CAMERON A. The metabolic syndrome: validity and utility of clinical definitions for cardiovascular disease and diabetes risk prediction. *Maturitas* **65**: 117-21, 2010.
- CARR MC. The emergence of the metabolic syndrome with menopause. *J Clin Endocrinol Metab* **88**: 2404-11, 2003.
- CHO GJ, LEE JH, PARK HT, SHIN JH, HONG SC, KIM T, HUR JY, LEE KW, PARK YK, KIM SH. Postmenopausal status according to years since menopause as an independent risk factor for the metabolic syndrome. *Menopause* **15**: 524-9, 2008.
- CÍFKOVÁ R, PÍŤHA J, LEJSKOVÁ M, LÁNSKÁ V, ŽECOVÁ S. Blood pressure around the menopause: a population study. *J Hypertens* **26**: 1976-82, 2008.
- CLARK C, SMITH W, LOCHNER A, DU TOIT EF. The effects of gender and obesity on myocardial tolerance to ischemia. *Physiol Res* **60**: 291-301, 2011.
- FENG Y, HONG X, WILKER E, LI Z, ZHANG W, JIN D, LIU X, ZANG T, XU X, XU X. Effects of age at menarche, reproductive years, and menopause on metabolic risk factors for cardiovascular diseases. *Atherosclerosis* **196**: 590-7, 2008.
- GRUNDY SM *et al.* Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults. NIH Publication No. 01-3670: 16 <http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3xsum.pdf>, 2001.
- INDHAVIVADHANA S, RATTANACHAIYANONT M, WONGVANANURAK T, KANBOON M, TECHATRAISAK K, LEERASIRI P, TANMAHASAMUT P, ANGSUWATHANA S. Predictors for metabolic syndrome in perimenopausal and postmenopausal Thai women. *Climacteric* **14**: 58-65, 2011.
- INGELSSON E, SCHAEFER EJ, CONTOIS JH, MCNAMARA JR, SULLIVAN L, KEYES MJ, PENCINA MJ, SCHOONMAKER C, WILSON PW, D'AGOSTINO RB, VASAN RS. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women. *JAMA* **298**: 776-85, 2007.
- JANSSEN I, POWELL LH, CRAWFORD S, LASLEY B, SUTTON-TYRRELL K. Menopause and the metabolic syndrome: the Study of Women's Health Across the Nation. *Arch Intern Med* **168**: 1568-75, 2008.
- KATZ A, NAMBI SS, MATHER K, BARON AD, FOLLMANN DA, SULLIVAN G, QUON MJ. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. *J Clin Endocrinol Metab* **85**: 2402-10, 2000.

- KINOSIAN B, GLICK H, GARLAND G. Cholesterol and coronary heart disease: predicting risks by levels and ratios. *Ann Intern Med* **121**: 641–647, 1994.
- LEJSKOVÁ M, ALUŠÍK Š, SUCHÁNEK M, ŽECOVÁ S, PÍŤHA J. Clustering of metabolic syndrome components without an increase in insulin resistance. *Climacteric* **14**: 83-91, 2011.
- MCKINLAY SM, BRAMBILLA DJ, POSNER JG. The normal menopause transition. *Maturitas* **61**: 4-16, 2008.
- MEISINGER C, THORAND B, SCHNEIDER A, STIEBER J, DÖRING A, LÖWEL H. Sex differences in risk factors for incident type 2 diabetes mellitus. The MONICA Augsburg Cohort Study. *Arch Intern Med* **162**: 82–89, 2002.
- MESCH VR, BOERO LE, SISELES NO, ROYER M, PRADA M, SAYEGH F, SCHREIER L, BENENCIA HJ, BERG GA. Metabolic syndrome throughout the menopausal transition: influence of age and menopausal status. *Climacteric* **9**: 40-8, 2006.
- MOEBUS S, HANISCH JU, AIDELSBURGER P, BRAMLAGE P, WASEM J, JÖCKEL KH. Impact of 4 different definitions used for the assessment of the prevalence of the Metabolic Syndrome in primary healthcare: The German Metabolic and Cardiovascular Risk Project (GEMCAS). *Cardiovasc Diabetol* **6**: 22, 2007.
- ROGER VL, GO AS, LLOYD-JONES DM *et al*. Heart disease and stroke statistics—2011 update: a report from the American Heart Association. *Circulation* **123**: e18-e209, 2011.
- SOULES MR, SHERMAN S, PARROTT E, REBAR R, SANTORO N, UTIAN W, WOODS N. Executive summary: Stages of Reproductive Aging Workshop (STRAW). *Climacteric* **4**: 267-72, 2001.
- TEEDE HJ, LOMBARD C, DEEKS AA. Obesity, metabolic complications and the menopause: an opportunity for prevention. *Climacteric* **13**: 203-9, 2010.

**Table 1 Main characteristics of women according to menopausal status (mean  $\pm$  SD or %)**

	Premenopause n = 351 [0;33]	Perimenopause n = 95 [33;366]	Postmenopause n = 129 [366;inf]
<b>Last menstrual period/subgroup interval (days)</b>			
<b>a) CONTINUOUS VARIABLES</b>			
Age (yrs)	48.6 $\pm$ 2.4	50.4 $\pm$ 2.3	52.2 $\pm$ 2.0*
Age at last menstrual period (yrs)	48.6 $\pm$ 2.4	50.1 $\pm$ 2.3	47.9 $\pm$ 3.6
Time since last menstrual period (days)	13 $\pm$ 8	119 $\pm$ 84	1574 $\pm$ 1129*
Follicle stimulated hormone (IU/l)	18.5 $\pm$ 20.6	55.0 $\pm$ 43.4	79.3 $\pm$ 34.1*
Total cholesterol (mmol/l)	5.44 $\pm$ 0.91	5.57 $\pm$ 0.90	5.88 $\pm$ 0.80*
Non-HDL cholesterol (mmol/l)	3.82 $\pm$ 0.95	3.88 $\pm$ 0.92	4.31 $\pm$ 0.93*
LDL cholesterol (mmol/l)	3.30 $\pm$ 0.82	3.39 $\pm$ 0.83	3.68 $\pm$ 0.82*
HDL cholesterol (mmol/l)	1.63 $\pm$ 0.38	1.69 $\pm$ 0.39	1.57 $\pm$ 0.37
Triglycerides (mmol/l)	1.31 $\pm$ 0.75	1.20 $\pm$ 0.49	1.57 $\pm$ 0.98*
Apolipoprotein B (g/l)	1.02 $\pm$ 0.25	0.99 $\pm$ 0.26	1.12 $\pm$ 0.29*
Apolipoprotein A1 (g/l)	1.65 $\pm$ 0.30	1.64 $\pm$ 0.25	1.61 $\pm$ 0.26
Apolipoprotein B/Apolipoprotein A1	0.63 $\pm$ 0.18	0.62 $\pm$ 0.20	0.72 $\pm$ 0.21*
LDL cholesterol/HDL cholesterol	2.18 $\pm$ 0.86	2.16 $\pm$ 0.89	2.52 $\pm$ 0.93*
Total cholesterol/HDL cholesterol	3.53 $\pm$ 1.02	3.47 $\pm$ 1.03	3.98 $\pm$ 1.18*
Waist circumference (cm)	85.1 $\pm$ 11.6	88.8 $\pm$ 14.9	91.4 $\pm$ 14.1*
Waist-to-hip ratio	0.83 $\pm$ 0.07	0.85 $\pm$ 0.07	0.86 $\pm$ 0.08*
Body mass index (kg/m <sup>2</sup> )	25.7 $\pm$ 4.4	26.5 $\pm$ 6.1	27.5 $\pm$ 6.0*
Hip circumference (cm)	102.1 $\pm$ 9.2	104.1 $\pm$ 11.9	105.9 $\pm$ 10.9*
SBP (mmHg)	119 $\pm$ 16	120 $\pm$ 16	121 $\pm$ 17
DBP (mmHg)	79 $\pm$ 10	80 $\pm$ 11	80 $\pm$ 10
Fasting plasma glucose (mmol/l)	5.2 $\pm$ 0.9	5.2 $\pm$ 0.7	5.4 $\pm$ 1.6
Fasting plasma insulin (IU/ml)	6.6 $\pm$ 4.0	7.1 $\pm$ 4.2	6.6 $\pm$ 3.7
HOMA-IR	1.54 $\pm$ 1.03	1.69 $\pm$ 1.09	1.72 $\pm$ 1.85
QUICKI	0.37 $\pm$ 0.04	0.37 $\pm$ 0.03	0.37 $\pm$ 0.04
<b>b) CATEGORICAL VARIABLES</b>			
MS NCEP-2001 (without therapy)	11.40%	11.58%	24.81%*
MS NCEP-2001 (G + BP therapy)	13.11%	13.68%	26.36%*
MS NCEP-2001 (G + BP + LIP therapy)	13.68%	13.68%	27.91%*
MS NCEP-2001 (G + BP + LIP therapy), non-smokers	11.11%	13.04%	19.61%*
Harmonizing MS (fasting glucose cut point $\geq$ 6.1 mmol/l)	18.23%	18.95%	31.78%*
Harmonizing MS (waist circumference cut point $\geq$ 88 cm)	16.81%	23.16%	33.33%*
Harmonizing MS 2009	23.08%	29.47%	37.21%*
Harmonizing MS 2009, non-smokers	21.21%	23.91%	33.33%*
Waist circumference $\geq$ 88 cm	35.61%	43.16%	51.16%*
Waist circumference $\geq$ 80 cm	63.53%	71.58%	79.84%*
Triglycerides $\geq$ 1.7 mmol/l	20.51%	20.00%	26.36%
HDL cholesterol $<$ 1.3 mmol/l	19.43%	12.63%	27.13%
Fasting glucose $\geq$ 6.1 mmol/l or a history of diabetes	4.30%	3.16%	10.08%*
Fasting glucose $\geq$ 5.6 mmol/l or a history of diabetes	19.20%	25.26%	31.78%*
SBP $\geq$ 130 mmHg	22.22%	25.26%	31.78%*
DBP $\geq$ 85 mmHg	24.50%	27.37%	28.68%
SBP $\geq$ 130mmHg or DBP $\geq$ 85mmHg	31.05%	32.63%	36.43%
SBP $\geq$ 130mmHg or DBP $\geq$ 85mmHg or BP-lowering ther.	37.04%	41.05%	43.41%
Blood pressure-lowering therapy	12.82%	12.63%	18.60%
Cholesterol-lowering therapy (statins)	3.42%	9.47%	7.81%
Triglyceride-lowering therapy (fibrates)	0.28%	1.05%	3.88%*
Smoking	43.6%	51.6%	60.2%*

\*  $p < 0.01$  for the difference between the Premenopause and Postmenopause groups.

SBP, Systolic Blood Pressure; DBP, Diastolic Blood Pressure, HOMA-IR, HOmeostasis Model Assessment of Insulin Resistance = (fasting plasma glucose; mmol/l)  $\times$  (fasting plasma insulin; mU/l)/22.5), QUICKI, QUAntitative Insulin sensitivity ChecK Index =  $1/(\log(\text{fasting plasma insulin, mU/l}) + \log(\text{fasting plasma glucose, mmol/l}) + \log 18.01)$  (Katz et al. 2000)

**Figure 1 Metabolic syndrome, metabolic syndrome components and other factors**

Age-adjusted effect sizes with 95% confidence intervals. Summaries of effect sizes for categorical variables are presented as odds ratios with 95% confidence intervals.

▲ Perimenopause (menopausal transition); ◆ Postmenopause




Table of data for Figure 1

	Age	Perimenopause	Postmenopause
<b>CATEGORICAL VARIABLES</b>			
<b>MS NCEP-2001</b>	1.036 [0.931;1.151] ns	0.957 [0.459;1.995] ns	2.264 [1.191;4.301] <0.05
<b>MS NCEP-2001 (G + BP therapy)</b>	1.055 [0.954;1.168] ns	0.955 [0.481;1.897] ns	1.954 [1.057;3.613] <0.05
<b>MS NCEP-2001 (G + BP + LIP therapy)</b>	1.058 [0.957;1.168] ns	0.907 [0.458;1.795] ns	2.002 [1.094;3.660] <0.05
<b>Harmonizing MS; glycemia 6.1 cut point</b>	1.078 [0.985;1.180] <0.01	0.918 [0.502;1.677] ns	1.598 [0.915;2.794] ns
<b>Harmonizing MS; waist 88 cm cut point</b>	1.138 [1.038;1.248] <0.01	1.192 [0.670;2.125] ns	1.573 [0.901;2.747] ns
<b>Harmonizing MS</b>	1.133 [1.042;1.232] <0.01	1.121 [0.660;1.903] ns	1.269 [0.751;2.143] ns
<b>High blood pressure</b>	1.081 [1.000;1.169] =0.05	0.936 [0.565;1.552] ns	0.960 [0.577;1.597] ns
<b>High BP or BP therapy</b>	1.111 [1.030;1.197] <0.01	0.984 [0.606;1.597] ns	0.894 [0.546;1.463] ns
<b>CONTINUOUS VARIABLES</b>			
<b>Waist circumference</b>	0.635 [0.175;1.095] <0.01	2.591 [-0.410;5.592] ns	4.022 [0.953;7.091] <0.05
<b>Body mass index</b>	0.188 [0.004;0.373] <0.05	0.519 [-0.685;1.723] ns	1.113 [-0.118;2.344] ns
<b>Log-Triglycerides</b>	0.020 [0.003;0.037] <0.05	-0.089 [-0.199;0.020] ns	0.076 [-0.036;0.187] ns
<b>Apolipoprotein B</b>	0.012 [0.002;0.021] <0.05	-0.049 [-0.111;0.013] ns	0.058 [-0.005;0.122] ns
<b>Glycemia</b>	0.006 [0.001;0.011] <0.05	0.007 [-0.026;0.039] ns	0.021 [-0.012;0.055] ns
<b>Systolic blood pressure</b>	0.758 [0.179;1.336] <0.05	-0.518 [-4.296;3.260] ns	-0.548 [-4.412;3.315] ns
<b>HDL cholesterol</b>	0.001 [-0.013;0.014] ns	0.064 [-0.026;0.154] ns	-0.057 [-0.149;0.035] ns
<b>Insulin</b>	0.030 [-0.115;0.174] ns	0.466 [-0.475;1.406] ns	-0.127 [-1.100;0.846] ns
<b>Log-HOMA-IR</b>	0.003 [-0.020;0.026] ns	0.109 [-0.040;0.258] ns	0.055 [-0.099;0.210] ns
<b>Diastolic blood pressure</b>	0.168 [-0.185;0.521] ns	0.001 [-2.305;2.307] ns	-0.272 [-2.630;2.085] ns



## Figure 2 Cholesterol parameters and lipid ratios

Age-adjusted effect sizes with 95% confidence intervals.

▲ Perimenopause (menopausal transition); ◆ Postmenopause




Table of data for Fig. 2

	Age	Perimenopause	Postmenopause
<b>CHOLESTEROL PARAMETERS</b>			
Total cholesterol	0.047, [0.015;0.079] <0.01	0.043, [-0.164;0.250] ns	0.266, [0.054;0.478] <0.05
Non-HDL cholesterol	0.047, [0.013;0.081] <0.01	-0.023, [-0.244;0.198] ns	0.320, [0.094;0.547] <0.01
LDL cholesterol	0.041, [0.011;0.070] <0.01	0.024, [-0.168;0.216] ns	0.238, [0.041;0.435] <0.05
<b>LIPID RATIOS</b>			
LDL cholesterol/ HDL cholesterol	0.029, [-0.003;0.061] ns	-0.072, [-0.280;0.136] ns	0.237, [0.025;0.450] <0.05
Total cholesterol/HDL cholesterol	0.035, [-0.003;0.073] ns	-0.117, [-0.366;0.132] ns	0.327, [0.072;0.582] <0.05
Apolipoprotein B/ A1	0.006, [-0.001;0.013] ns	-0.021, [-0.067;0.025] ns	0.059, [0.013;0.106] <0.05